NZ606281A - 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof - Google Patents
2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereofInfo
- Publication number
- NZ606281A NZ606281A NZ606281A NZ60628111A NZ606281A NZ 606281 A NZ606281 A NZ 606281A NZ 606281 A NZ606281 A NZ 606281A NZ 60628111 A NZ60628111 A NZ 60628111A NZ 606281 A NZ606281 A NZ 606281A
- Authority
- NZ
- New Zealand
- Prior art keywords
- dihydropyrido
- pyrimidine
- oxo
- amino
- carbonitrile
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 208000035475 disorder Diseases 0.000 abstract 4
- 230000002062 proliferating effect Effects 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 4-(4-methylpiperazin-1-yl)anilinyl Chemical group 0.000 abstract 2
- VADOZMZXXRBXNY-UHFFFAOYSA-N 8-cyclopentyl-2-[4-(4-methylpiperazin-1-yl)anilino]-7-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical class C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=C(C#N)C(=O)N2C3CCCC3)C2=N1 VADOZMZXXRBXNY-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- UKXZJPKVKAIBRI-UHFFFAOYSA-N 8-cyclohexyl-2-[4-(4-methylpiperazin-1-yl)anilino]-7-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=C(C#N)C(=O)N2C3CCCCC3)C2=N1 UKXZJPKVKAIBRI-UHFFFAOYSA-N 0.000 abstract 1
- DDLUGPZFSDJARE-UHFFFAOYSA-N 8-cyclopentyl-2-(3,5-dimethoxyanilino)-7-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound COC1=CC(OC)=CC(NC=2N=C3N(C4CCCC4)C(=O)C(C#N)=CC3=CN=2)=C1 DDLUGPZFSDJARE-UHFFFAOYSA-N 0.000 abstract 1
- XGTHJEPWJGOISN-UHFFFAOYSA-N 8-cyclopentyl-2-(4-morpholin-4-ylanilino)-7-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound N1=C2N(C3CCCC3)C(=O)C(C#N)=CC2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 XGTHJEPWJGOISN-UHFFFAOYSA-N 0.000 abstract 1
- YNDJCUZGIVBCGR-UHFFFAOYSA-N 8-cyclopentyl-7-oxo-2-(3,4,5-trimethoxyanilino)pyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C3N(C4CCCC4)C(=O)C(C#N)=CC3=CN=2)=C1 YNDJCUZGIVBCGR-UHFFFAOYSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 208000001708 Dupuytren contracture Diseases 0.000 abstract 1
- 206010029098 Neoplasm skin Diseases 0.000 abstract 1
- 208000009905 Neurofibromatoses Diseases 0.000 abstract 1
- 208000004362 Penile Induration Diseases 0.000 abstract 1
- 208000020758 Peyronie disease Diseases 0.000 abstract 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 206010038934 Retinopathy proliferative Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 230000001919 adrenal effect Effects 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 208000016738 bone Paget disease Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 208000011803 breast fibrocystic disease Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000024519 eye neoplasm Diseases 0.000 abstract 1
- 210000000232 gallbladder Anatomy 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000011379 keloid formation Diseases 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 230000001926 lymphatic effect Effects 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 abstract 1
- 201000004931 neurofibromatosis Diseases 0.000 abstract 1
- 230000002611 ovarian Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
- 208000035803 proliferative type breast fibrocystic change Diseases 0.000 abstract 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 230000002381 testicular Effects 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37094610P | 2010-08-05 | 2010-08-05 | |
| PCT/US2011/044807 WO2012018540A1 (en) | 2010-08-05 | 2011-07-21 | 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidine-6-carbonitriles and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ606281A true NZ606281A (en) | 2014-09-26 |
Family
ID=45559737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ606281A NZ606281A (en) | 2010-08-05 | 2011-07-21 | 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8987267B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2600719B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5512894B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101434841B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103200822B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011286282B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013002375B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2807498C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2600719T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA022527B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2525866T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL224555A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2013001427A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ606281A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2600719T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2600719E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012018540A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8987267B2 (en) * | 2010-08-05 | 2015-03-24 | Temple University—Of the Commonwealth System of Higher Education | 2-substituted-8-alkyl-7-OXO-7,8-dihydropyrido[2,3-D]pyrimidine-6-carbonitriles and uses thereof in treating proliferative disorders |
| WO2014031571A1 (en) * | 2012-08-21 | 2014-02-27 | Icahn School Of Medicine At Mount Sinai | Treatment of viral infections |
| EP2968331B1 (en) | 2013-03-14 | 2020-07-01 | Icahn School of Medicine at Mount Sinai | Pyrimidine compounds as kinase inhibitors |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| US9828373B2 (en) | 2014-07-26 | 2017-11-28 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof |
| CN104447739B (zh) * | 2014-11-07 | 2016-02-17 | 郑州泰基鸿诺药物科技有限公司 | 一种氘代Palbociclib衍生物、制备方法及应用 |
| CN104447743B (zh) * | 2014-11-26 | 2016-03-02 | 苏州明锐医药科技有限公司 | 帕博西尼的制备方法 |
| CN104496983B (zh) | 2014-11-26 | 2016-06-08 | 苏州明锐医药科技有限公司 | 一种帕博西尼的制备方法 |
| CN104478874B (zh) * | 2014-12-08 | 2016-03-02 | 新发药业有限公司 | 一种帕博赛布的制备方法 |
| CN104610254B (zh) * | 2015-01-26 | 2017-02-01 | 新发药业有限公司 | 一种帕博赛布的低成本制备方法 |
| CN105111205B (zh) * | 2015-09-12 | 2017-01-04 | 山东罗欣药业集团股份有限公司 | 一种帕博西尼的制备方法 |
| AU2017374721B2 (en) | 2016-12-16 | 2021-02-25 | Cstone Pharmaceuticals | CDK4/6 inhibitor |
| JP2021514359A (ja) | 2018-02-15 | 2021-06-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | キナーゼ阻害剤としての複素環式化合物 |
| KR102286701B1 (ko) * | 2018-09-28 | 2021-08-06 | 재단법인 대구경북첨단의료산업진흥재단 | 피리도[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| TWI818930B (zh) * | 2018-11-12 | 2023-10-21 | 美商昂可諾法治療股份有限公司 | 8-環戊基-7-側氧基-2-(4-哌嗪-1-基-苯基胺基)-7,8-二氫-吡啶[2,3-d]嘧啶-6-氰基及其用於治療增生性疾病的用途 |
| CN112969463A (zh) * | 2018-11-12 | 2021-06-15 | 安哥洛华治疗公司 | 8-环戊基-7-氧代-2-(4-哌嗪-1-基-苯基氨基)-7,8-二氢-吡啶并[2,3-d]嘧啶-6-腈及其在治疗增殖性疾病中的用途 |
| US20220220103A1 (en) * | 2018-12-28 | 2022-07-14 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| AU2019413683B2 (en) * | 2018-12-28 | 2025-05-22 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| AU2020300586A1 (en) * | 2019-07-02 | 2022-02-17 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| WO2021108803A1 (en) | 2019-11-26 | 2021-06-03 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as jak inhibitors |
| US20230132667A1 (en) * | 2020-05-28 | 2023-05-04 | University Of Washington | Drug-like molecules and methods for the therapeutic targeting of viral rna structures |
| JP2024540411A (ja) | 2021-11-08 | 2024-10-31 | プロジェントス・セラピューティクス・インコーポレイテッド | 血小板由来成長因子受容体（ｐｄｇｆｒ）アルファ阻害剤及びその使用 |
| CN118678960A (zh) * | 2021-11-18 | 2024-09-20 | 安可诺瓦治疗公司 | 用于治疗癌症的方法和组合物 |
| CN118574623A (zh) * | 2021-11-18 | 2024-08-30 | 安可诺瓦治疗公司 | 用于治疗癌症的方法和组合物 |
| WO2023230288A1 (en) * | 2022-05-25 | 2023-11-30 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| WO2024107730A1 (en) * | 2022-11-14 | 2024-05-23 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| EP4618992A1 (en) * | 2022-11-17 | 2025-09-24 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5620981A (en) | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| US6498163B1 (en) * | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| TR200003429T2 (tr) * | 1998-05-26 | 2001-07-23 | Warner-Lambert Company | Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler. |
| SK10772002A3 (sk) | 2000-01-27 | 2004-01-08 | Warner-Lambert Company | Pyridopyrimidinónové deriváty na liečbu neurodegeneratívnych ochorení |
| PL203805B1 (pl) * | 2000-02-25 | 2009-11-30 | Hoffmann La Roche | Zastosowanie cyklicznych związków heteroaromatycznych, lek i cykliczne związki heteroaromatyczne |
| CA2401368A1 (en) * | 2000-03-06 | 2001-09-27 | Warner-Lambert Company | 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
| KR100669578B1 (ko) | 2002-01-22 | 2007-01-15 | 워너-램버트 캄파니 엘엘씨 | 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온 |
| CA2555724A1 (en) | 2004-02-18 | 2005-09-09 | Warner-Lambert Company Llc | 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
| WO2005105097A2 (en) | 2004-04-28 | 2005-11-10 | Gpc Biotech Ag | Pyridopyrimidines for treating inflammatory and other diseases |
| US20060142312A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| GB0428475D0 (en) * | 2004-12-30 | 2005-02-02 | 4 Aza Bioscience Nv | Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
| MX2007007901A (es) * | 2004-12-30 | 2007-11-07 | 4 Aza Ip Nv | Pirido-(3,2-d)pirimidinas y composiciones farmaceuticas utiles para tratamiento medico. |
| AU2006261607A1 (en) * | 2005-06-24 | 2006-12-28 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis C. |
| BRPI0617159B8 (pt) * | 2005-10-07 | 2021-05-25 | Exelixis Inc | compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo |
| EA201200669A1 (ru) | 2005-10-07 | 2012-11-30 | Экселиксис, Инк. | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα |
| US20090191193A1 (en) | 2006-08-02 | 2009-07-30 | Temple University-Of The Commonwealth System Of Higher Education | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof |
| WO2008150260A1 (en) | 2007-06-06 | 2008-12-11 | Gpc Biotech, Inc. | 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents |
| EP2084159A1 (en) | 2006-10-16 | 2009-08-05 | GPC Biotech Inc. | Pyrido ý2, 3-d¨pyrimidines and their use as kinase inhibitors |
| JP5797664B2 (ja) | 2009-12-18 | 2015-10-21 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ | 置換ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン及びそれらの治療用の使用 |
| US8987267B2 (en) * | 2010-08-05 | 2015-03-24 | Temple University—Of the Commonwealth System of Higher Education | 2-substituted-8-alkyl-7-OXO-7,8-dihydropyrido[2,3-D]pyrimidine-6-carbonitriles and uses thereof in treating proliferative disorders |
-
2011
- 2011-07-21 US US13/813,023 patent/US8987267B2/en active Active
- 2011-07-21 JP JP2013523185A patent/JP5512894B2/ja not_active Expired - Fee Related
- 2011-07-21 AU AU2011286282A patent/AU2011286282B2/en active Active
- 2011-07-21 PL PL11815012T patent/PL2600719T3/pl unknown
- 2011-07-21 WO PCT/US2011/044807 patent/WO2012018540A1/en not_active Ceased
- 2011-07-21 EA EA201390199A patent/EA022527B1/ru not_active IP Right Cessation
- 2011-07-21 NZ NZ606281A patent/NZ606281A/en unknown
- 2011-07-21 PT PT118150127T patent/PT2600719E/pt unknown
- 2011-07-21 ES ES11815012.7T patent/ES2525866T3/es active Active
- 2011-07-21 DK DK11815012.7T patent/DK2600719T3/da active
- 2011-07-21 CA CA2807498A patent/CA2807498C/en active Active
- 2011-07-21 MX MX2013001427A patent/MX2013001427A/es active IP Right Grant
- 2011-07-21 EP EP11815012.7A patent/EP2600719B1/en active Active
- 2011-07-21 BR BR112013002375-9A patent/BR112013002375B1/pt active IP Right Grant
- 2011-07-21 CN CN201180038325.3A patent/CN103200822B/zh active Active
- 2011-07-21 KR KR1020137004979A patent/KR101434841B1/ko active Active
-
2013
- 2013-02-03 IL IL224555A patent/IL224555A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ES2525866T3 (es) | 2014-12-30 |
| DK2600719T3 (da) | 2014-12-15 |
| EA022527B1 (ru) | 2016-01-29 |
| MX2013001427A (es) | 2013-06-13 |
| AU2011286282A1 (en) | 2013-02-14 |
| EP2600719A1 (en) | 2013-06-12 |
| CA2807498A1 (en) | 2012-02-09 |
| US20130131058A1 (en) | 2013-05-23 |
| PT2600719E (pt) | 2014-12-22 |
| AU2011286282B2 (en) | 2014-08-21 |
| KR20130098314A (ko) | 2013-09-04 |
| BR112013002375B1 (pt) | 2020-05-12 |
| PL2600719T3 (pl) | 2015-03-31 |
| JP5512894B2 (ja) | 2014-06-04 |
| BR112013002375A2 (pt) | 2016-05-24 |
| IL224555A (en) | 2016-03-31 |
| WO2012018540A1 (en) | 2012-02-09 |
| EP2600719B1 (en) | 2014-10-08 |
| EP2600719A4 (en) | 2014-01-01 |
| JP2013538196A (ja) | 2013-10-10 |
| CN103200822B (zh) | 2014-12-24 |
| EA201390199A1 (ru) | 2013-07-30 |
| CA2807498C (en) | 2017-02-07 |
| CN103200822A (zh) | 2013-07-10 |
| US8987267B2 (en) | 2015-03-24 |
| KR101434841B1 (ko) | 2014-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ606281A (en) | 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof | |
| JP2013538196A5 (cg-RX-API-DMAC7.html) | ||
| ES2609767T3 (es) | Combinaciones de un inhibidor de PI3K y un inhibidor de MEK | |
| ES2703552T3 (es) | Nuevos derivados de pirimidina fusionados para la inhibición de la actividad de tirosina quinasa | |
| PH12017501661A1 (en) | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | |
| PH12013500742A1 (en) | Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as jak inhibitors | |
| JP2014521725A5 (cg-RX-API-DMAC7.html) | ||
| JP2020510032A5 (cg-RX-API-DMAC7.html) | ||
| RU2019101220A (ru) | Кристаллические формы соединения триазолопиримидина | |
| MX2013007148A (es) | 2-arilimidazo[1,2-b]piridazina, 2-fenilimidazo[1,2-a]pirimidina, y derivados de 2-fenilimidazo[1.2-a]pirazina. | |
| RU2014151850A (ru) | Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их | |
| RU2672910C9 (ru) | Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы | |
| RU2015124381A (ru) | Производные 2,3-дигидро-изоиндол-1-она и способы их применения в качестве ингибиторов тирозинкиназы брутона | |
| CA2473026A1 (en) | 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | |
| MX2013003036A (es) | Derivados de pirazina como bloqueadores de enac. | |
| PH12019500804A1 (en) | Liposomal formulation for use in the treatment of cancer | |
| JP2015512943A5 (cg-RX-API-DMAC7.html) | ||
| RU2612251C2 (ru) | Соединения диоксин- и оксазин[2,3-d]пиримидина в качестве ингибиторов фосфоинозитид-3-киназы и способы их применения | |
| JP2015524450A5 (cg-RX-API-DMAC7.html) | ||
| ES2616441T3 (es) | Derivados de N-(piridin-2-il))pirimidin-4-amina que contienen un grupo sulfona | |
| JP2021147340A (ja) | 化合物、そのナノ粒子及び癌疾患の治療剤 | |
| EP3723757A1 (en) | Small molecule degraders that recruit dcaft15 | |
| JP2010523677A (ja) | 癌の治療のためのＰＩ３Ｋα阻害剤としてのピリド［２，３−Ｄ］ピリミジン−７−オン | |
| JP2018534314A5 (cg-RX-API-DMAC7.html) | ||
| ES2937810T3 (es) | Derivado de sulfonamida con esqueleto de cumarina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUL 2016 BY COMPUTER PACKAGES INC Effective date: 20150701 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUL 2017 BY COMPUTER PACKAGES INC Effective date: 20160701 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUL 2018 BY COMPUTER PACKAGES INC Effective date: 20170701 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUL 2019 BY COMPUTER PACKAGES INC Effective date: 20180703 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUL 2020 BY COMPUTER PACKAGES INC Effective date: 20190702 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUL 2021 BY COMPUTER PACKAGES INC Effective date: 20200701 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUL 2022 BY COMPUTER PACKAGES INC Effective date: 20210630 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUL 2023 BY COMPUTER PACKAGES INC Effective date: 20220630 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUL 2024 BY COMPUTER PACKAGES INC Effective date: 20230630 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUL 2025 BY COMPUTER PACKAGES INC Effective date: 20240630 |